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eighth ENBDC workshop “Methods in
Mammary Gland Development and Cancer”
Bethan Lloyd-Lewis1†, Anoeska A. A. van de Moosdijk2†, Mohamed Bentires-Alj3, Robert B. Clarke4
and Renée van Amerongen2*Abstract
The ENBDC workshop “Methods in Mammary Gland Development and Cancer” is an established international forum
to showcase the latest technical advances in the field. The eighth meeting focused on emerging concepts and
technologies for studying normal and neoplastic breast development.Introduction and keynote
Along the shores of Lake Lucerne scientists working on
breast development and cancer gathered in Weggis for
the annual European Network for Breast Development
and Cancer (ENBDC) workshop. The uncharacteristic
downpours failed to dampen the enthusiasm of partici-
pants, fuelled by high-caliber talks and the exchange of
cutting-edge insights relevant to mammary gland biology.
This year’s keynote lecture was given by Jos Jonkers
(Netherlands Cancer Institute, Amsterdam, the Netherlands).
He discussed how gene targeting in embryonic stem cell lines
derived from already existing genetically engineered
mouse models, so-called GEMM-ESCs, has greatly im-
proved his lab’s efficiency to generate complex compound
mouse models [1]. This allows a relatively rapid in vivo
analysis of a gene’s contribution to the breast cancer
phenotype, response to therapy, and resistance to treat-
ment. He illustrated this by discussing the effects of onco-
genic Met expression on top of Brca1 and p53 loss [2]. His
lab is also experimenting with CRISPR/Cas9 and Jonkers
warned that local delivery of Cas9 appears to trigger an
immune response, which researchers should bear in
mind when applying Cas9 somatically [3].* Correspondence: R.vanAmerongen@uva.nl
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and high throughput screening (Chair: Mohamed
Bentires-Alj)
Anne-Lise Børresen-Dale (Institute for Cancer Research,
Oslo, Norway) described breast tumor heterogeneity as
the biggest challenge for translating biological findings
into the clinic. Børresen-Dale and collaborators have
taken a holistic view and use a patient directed “sys-
tems medicine” approach to understand how inter- and
intra-tumor heterogeneity affects response to therapy
and patients’ outcome [4, 5]. Their multilevel approach
includes molecular analyses of breast cancer: assessment of
DNA copy number variations, mutation and methyla-
tion, as well as alterations in RNAs, microRNAs, long-
noncoding RNAs, proteins, and metabolites. It also
comprises imaging (i.e., mammograms and CT/MRI/PET)
and clinical and pathology-based classification. It remains
unclear which levels best capture both the intra- and inter-
tumor heterogeneity important for treatment decisions,
and algorithms that integrate data from all levels are still
missing.
Luca Magnani (Imperial College, London, UK) described
how tumors evolve (epi)genetically and linked these
alterations to biomechanical changes in the tumor.
Long-term estrogen-deprived (LTED) cells that became
resistant to aromatase inhibitors (AI) acquire metastatic
potential and increase the expression of genes involved
in cholesterol biosynthesis. AI-resistant cells upregulatele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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α (ERα) to promote invasion, which can be attenuated
with anti-cholesterol treatment. This suggests that a bio-
marker signature based on cholesterol biosynthesis might
be used to stratify patients prior to adjuvant endocrine
therapies [6]. Also, the keratin type II locus topological
associating domain (TAD) is among the top 5% of hyper-
acetylated TADs in LTED AI-resistant cells. Keratin80
(K80) is upregulated by cholesterol and was found to be
the driver within the TAD. Of note, K80 is overexpressed
in metastatic breast cancers and seems to increase intra-
cellular stiffness. They also identified copy number vari-
ation as a potential mechanism of AI resistance, which
may synergize with epigenetic reprogramming to drive the
development of an estrogen-independent niche within
metastatic tissue.
Francesca Buffa (University of Oxford, UK) discussed
in silico systems biology and functional genomics ap-
proaches to accelerate biomarker discovery. She used in
silico co-expression networks to define pathways from
human cancer samples and developed “SEARCH”: SEed
Agglomerative and Recursive Clustering with Hypothesis
oriented initialization. SEARCH exploits knowledge of
cancer pathways to construct a gene network of a given
cancer phenotype (e.g., hypoxia, angiogenesis) and derive
a signature [7]. Signatures were validated in human breast
cancer samples and are currently being tested for whether
they are generalizable to other tumors.Session 2: PhD and postdoc session (Chairs:
Bethan Lloyd-Lewis and Anoeska van de
Moosdijk)
For the first time in the meeting’s history, the floor was
briefly entrusted to the next generation of researchers in
the PhD and postdoc session. David Bryant (University
of Glasgow, UK) discussed the application of three-
dimensional (3D) organoid cultures to investigate col-
lective cancer cell invasion. He provided a historical
overview and critical assessment of 3D culture, before
presenting the approaches undertaken in his laboratory to
study cell polarity and invasion in prostate cancer. Using
immortalized and tumor cell lines grown in Matrigel, he
showed how the scratchwound assay could be adapted to
3D. Combined with time-lapse imaging, this approach
provided high-resolution insights into the role of IQSEC1
(a guanine nucleotide exchange factor for ARF6) in
cell invasion, with knockdown cells failing to repopu-
late the scratched area despite showing protrusion
formation (unpublished data). He underlined the im-
portance of studying cell behavior on a population
level and is currently developing automated image
segmentation for high-throughput analysis of organoid
cultures.Session 3: Emerging models and technologies
(Chair: Renée van Amerongen)
Pekka Katajisto (University of Helsinki, Finland) discussed
his search to identify an in vitro system that showed nice
asymmetric cell division and shared his eureka moment
when he found immortalized human mammary epithelial
cells (HMECs), which ultimately allowed him to dem-
onstrate the age-selective segregation of mitochondria
[8]. He showed how the SNAP-tag technology [9],
which facilitates the attachment of fluorophores to spe-
cific proteins in live cells, allows stress-free labeling of
differently aged organelles with multiple fluorochromes,
enabling pulse-chase experiments while preventing damage
to the mitochondria.
Walid Khaled (University of Cambridge, UK) talked
about his efforts to elucidate the role of BCL11A in
triple-negative breast cancer [10]. Using rapid immuno-
precipitation mass spectrometry of endogenous proteins
(RIME), his team is characterizing the BCL11A interac-
tome. He also discussed the intricacies associated with
generating a CRISPR reporter cell line via homology
directed repair (HDR), stressing that the targeting effi-
ciency greatly depends on both the cell line and sgRNA
design.
Sara Wickström (Max Planck Institute for Biology of
Ageing, Cologne, Germany) talked about the regulation
of epidermal stem cell fate, stressing the importance of
stochasticity. Whereas cells typically show self-organization
into a functional tissue, it can be difficult to predict cell fate
decisions for individual cells in the population. Her group
found that, quite unexpectedly, hair follicle stem and
progenitor cells interconvert equally in both directions
(Chacon-Martinez et al., submitted). She showed how
mechanical strain can influence cell fate decisions by
re-arranging the chromatin structure in the nucleus, a
process that involves transcriptional silencing by the
Polycomb complex [11].
Session 4: Cell identity and plasticity in the
mammary gland (Chair: Rob Clarke)
Christina Scheel (Helmholtz Centre, Munich, Germany)
presented on epithelial plasticity in human mammary
gland morphogenesis and breast cancer progression. She
discussed a novel 3D culture method for normal human
breast epithelium [12]. Human breast epithelial cells ob-
tained from reduction mammoplasties were cultured as
organoids in floating collagen I gels in medium containing
bovine pituitary extract and forskolin. This system enables
normal breast epithelial cells to be passaged in vitro
and forskolin prevents epithelial–mesenchymal transi-
tion (EMT), which otherwise prevents the formation of
organoids that resemble Terminal-Ductal lobular units
(TDLUs). She also highlighted a model of EMT in breast
cells that advances our understanding of its importance in
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breast epithelial (HMLE) cells were transduced with a
tamoxifen-inducible TWIST gene (HMLE-Twist-ER).
Treatment of HMLE-Twist-ER cells with tamoxifen induces
EMT defined by CD44 expression and mammosphere for-
mation. Subsequent withdrawal of tamoxifen reveals three
populations, including CD44+CD24+ cells, which retain
epithelial characteristics and have enriched mammosphere-
forming ability. These cells originate from HMLE cells that
express TGF-beta receptor type 1 and WNT5a and are
potentially more active in lung colonization than cells that
have transdifferentiated to a mesenchymal state.
Beatrice Howard (Institute of Cancer Research, London,
UK) discussed embryonic mammary cell identity and plasti-
city. It is known that embryonic day 12.5 (E12.5) mammary
gland primordia can repopulate a cleared adult mammary
fat pad and that mammary-repopulating units increase as
the embryonic gland matures. However, the factors regulat-
ing this remain unknown. As the organ initially forms, Hox,
Wnt, and stem cell genes such as Edar and Nrg3 are highly
expressed. Nrg3−/− mice have an embryonic phenotype with
absent or hypoplastic mammary organs composed of cells
that have not been specified to the mammary phenotype
[14]. To facilitate mutant phenotypic studies, several
embryonic mammary cell lines have been developed by
cloning them out in 3D culture. These have some distinctive
phenotypes, including expression of specific adult stem cell
markers such as Sox9 and Procr and capacity to form
partial post-natal mammary epithelial outgrowths.
Conclusions
The invited speakers were supported by nine selected
short talks, with the first ENBDC DeOme prize for best
talk awarded to Colinda Scheele (Hubrecht Institute,
Utrecht, the Netherlands). Also, Bethny Morrissey
(Leeds Institute of Cancer and Pathology, UK) publicized
SEARCHBreast (https://searchbreast.org), a resource that
facilitates sharing of material from in vivo breast cancer
models [15]. Lively poster sessions and a collegial atmos-
phere fostered the dissemination of ideas and technical
experiences between participants. Overall, the annual
ENBDC workshop reaffirmed its position as an essential
forum for discussion in the mammary gland and breast
cancer field. The ninth ENBDC workshop, on 9–11 March
2017, will be chaired by Richard Iggo (Institut Bergonie,
Bordeaux, France) and the PhD and postdoc session by
Katrin Wiese (University of Amsterdam, the Netherlands)
and Romain Amante (Friedrich Miescher Institute for
Biomedical research, Basel, Switzerland).
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